---
figid: PMC11586797__98550-g001
figtitle: 'Mammalian target of rapamycin signaling pathway and its interaction with
  EZH2 expression in hepatocellular carcinoma: Mechanisms and implications'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11586797
filename: 98550-g001.jpg
figlink: /pmc/articles/PMC11586797/figure/F1/
number: F1
caption: 'Mammalian target of rapamycin signaling pathway and its interaction with
  EZH2 expression in hepatocellular carcinoma: Mechanisms and implications. Illustration
  of the mammalian target of rapamycin (mTOR) signaling pathway and its interaction
  with EZH2 expression in hepatocellular carcinoma (HCC). The figure highlights key
  components of the mTOR pathway, including upstream regulators (e.g., PI3K/AKT) and
  downstream effectors that influence cell proliferation, survival, and metabolism.
  EZH2, a critical epigenetic regulator, is shown to be modulated by mTOR signaling,
  contributing to tumor progression, invasion, and poor prognosis in HCC. The interplay
  between mTOR activation and elevated EZH2 expression suggests a mechanistic link
  that promotes cancer aggressiveness, making these pathways potential therapeutic
  targets. Arrows indicate signaling cascades and molecular interactions involved
  in HCC development. HCC: Hepatocellular carcinoma; IRS: Insulin receptor substrate;
  PI3K: Phosphoinositide 3-kinase; PTEN: Phosphatase and tensin homologue; PDK1: 3-Phosphoinositide-dependent
  kinase 1; AKT: Protein kinase B; mTOR: Mammalian target of rapamycin; EZH2: Enhancer
  of zeste homolog 2'
papertitle: 'Radiomics and molecular analysis: Bridging the gap for predicting hepatocellular
  carcinoma prognosis'
reftext: Chun-Han Cheng, et al. World J Clin Cases. 2025 Feb 6;13(4).
year: '2025'
doi: 10.12998/wjcc.v13.i4.98550
journal_title: World Journal of Clinical Cases
journal_nlm_ta: World J Clin Cases
publisher_name: Baishideng Publishing Group Inc
keywords: Hepatocellular carcinoma | Computed tomography | Radiomics | Enhancer of
  zeste homologue 2 expression | Non-invasive imaging
automl_pathway: 0.9420998
figid_alias: PMC11586797__F1
figtype: Figure
redirect_from: /figures/PMC11586797__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11586797__98550-g001.html
  '@type': Dataset
  description: 'Mammalian target of rapamycin signaling pathway and its interaction
    with EZH2 expression in hepatocellular carcinoma: Mechanisms and implications.
    Illustration of the mammalian target of rapamycin (mTOR) signaling pathway and
    its interaction with EZH2 expression in hepatocellular carcinoma (HCC). The figure
    highlights key components of the mTOR pathway, including upstream regulators (e.g.,
    PI3K/AKT) and downstream effectors that influence cell proliferation, survival,
    and metabolism. EZH2, a critical epigenetic regulator, is shown to be modulated
    by mTOR signaling, contributing to tumor progression, invasion, and poor prognosis
    in HCC. The interplay between mTOR activation and elevated EZH2 expression suggests
    a mechanistic link that promotes cancer aggressiveness, making these pathways
    potential therapeutic targets. Arrows indicate signaling cascades and molecular
    interactions involved in HCC development. HCC: Hepatocellular carcinoma; IRS:
    Insulin receptor substrate; PI3K: Phosphoinositide 3-kinase; PTEN: Phosphatase
    and tensin homologue; PDK1: 3-Phosphoinositide-dependent kinase 1; AKT: Protein
    kinase B; mTOR: Mammalian target of rapamycin; EZH2: Enhancer of zeste homolog
    2'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - PTEN
  - EZH2
  - Nucleus
  - carcinoma
  - Hepatocellular carcinoma
---
